Form 4: Zai Lab CEO Du Ying Granted Significant Equity Awards

Zai Lab's Chairperson and CEO, Du Ying, received significant equity grants, including stock options and restricted share units, on March 11, 2026.

Summary

• Du Ying, Chairperson & CEO of Zai Lab Ltd (ZLAB), was granted 353,430 stock options and 32,419 Restricted Share Units (RSUs) on March 11, 2026.
• The stock options have an exercise price of $19.34 per American Depositary Share (ADS) and expire on March 11, 2036.
• Both the stock options and RSUs will vest in equal annual installments over four years, commencing on March 11, 2027, subject to continuous service.
• Each American Depositary Share (ADS) represents ten Ordinary Shares of Zai Lab Ltd.
• Vested RSU shares will be delivered to the reporting person in the form of ADSs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the significant equity grants to the Chairperson & CEO align management's long-term interests with shareholder value creation.

Positives

• The grant of significant equity awards to the Chairperson & CEO aligns management's long-term interests with those of shareholders, potentially incentivizing sustained performance.
• The vesting schedule over four years demonstrates a commitment to long-term leadership and company growth.

Future Outlook

The equity grants, with their multi-year vesting schedule, indicate an expectation of continued service and performance from the Chairperson & CEO, aligning her incentives with the company's long-term strategic goals and shareholder value creation.

Industry Context

StockSavvy.ai notes that granting equity awards such as stock options and restricted share units to top executives is a standard practice across the biotechnology and pharmaceutical industries. This compensation structure is designed to align the interests of management with those of shareholders, encouraging long-term value creation and retention of key talent in a highly competitive sector.

Comparison to Industry Standards

• The structure of equity compensation, involving both stock options and RSUs with multi-year vesting, is consistent with common practices observed in global biotech and pharmaceutical companies, such as Regeneron Pharmaceuticals or Moderna, which frequently use similar mechanisms to incentivize executive performance and retention.
• The specific number of shares and exercise price would require a detailed comparison against peer group compensation packages, considering company size, performance, and market capitalization, to assess if it falls within typical industry ranges.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of management's interests with long-term shareholder value.
• Employees: May signal stability and confidence in leadership, potentially boosting morale.

Next Steps

• The stock options and RSUs will begin vesting in equal annual installments starting March 11, 2027, over a four-year period.

Key Dates

Keywords

Zai Lab, ZLAB, Du Ying, Form 4, Stock Options, Restricted Share Units, RSU, Equity Grant, Executive Compensation, Insider Transaction